Analytical Data
-
Gene name
XCL2/SCM-1 beta
- Application
-
Alternative Names
SCYC2; SCM-1b; Small Inducible Cytokine Subfamily C Member 2; Cytokine SCM-1 beta; C motif chemokine 2; XC chemokine ligand 2
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UBD3
-
Expression Region
Val22~Gly114
-
Protein Length
Partial
-
Molecular Weight
42kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
XCL2, also known as SCM-1 beta, is a small cytokine belonging to the C chemokine family. It plays a crucial role in modulating immune responses, particularly in the attraction of lymphocytes to sites of inflammation and infection. The research surrounding XCL2/SCM-1 beta has gained momentum due to its implications in various autoimmune diseases, cancer, and viral infections. Elevated levels of this chemokine have been associated with disease progression, highlighting its potential as a biomarker for diagnostic and therapeutic purposes. Furthermore, XCL2's ability to selectively recruit lymphocytes, especially theC-C chemokine receptor type 4 (CCR4)-expressing T cells, positions it as a target for immunotherapeutic strategies. The production of recombinant XCL2/SCM-1 beta protein has become increasingly important for studying its biological functions, signaling pathways, and potential interactions with other immune modulators. This research not only elucidates the fundamental mechanisms of immune regulation but also opens avenues for the development of novel therapeutic interventions aimed at modulating the immune response in various pathological conditions.
